Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1094470 | 0.81 | ALDH1A1 (0.40) | APOBEC3GALDH1A1SMN1; SMN2KMT2AHSD17B10 | |
| SCHEMBL28093349 | 0.81 | ALDH1A1 (0.40) | APOBEC3GALDH1A1SMN1; SMN2KMT2AHSD17B10 | |
| SCHEMBL28335411 | 0.81 | GRM4 (0.45) | ALDH1A1SMN1; SMN2KMT2AHSD17B10GRM4 | |
| SCHEMBL1095054 | 0.77 | APOBEC3G (0.47) | APOBEC3GALDH1A1SMN1; SMN2KMT2AHSD17B10 | |
| SCHEMBL1094170 | 0.75 | APOBEC3G (0.57) | APOBEC3GALDH1A1SMN1; SMN2KMT2AHSD17B10 | |
| SCHEMBL21296528 | 0.75 | ALDH1A1 (0.38) | APOBEC3GALDH1A1SMN1; SMN2KMT2AHSD17B10 | |
| SCHEMBL1094961 | 0.74 | APOBEC3G (0.47) | APOBEC3GALDH1A1SMN1; SMN2KMT2AHSD17B10 | |
| SCHEMBL16177880 | 0.72 | APOBEC3G (0.48) | APOBEC3GALDH1A1SMN1; SMN2KMT2AHSD17B10 | |
| SCHEMBL27675592 | 0.72 | APOBEC3G (0.41) | APOBEC3GALDH1A1SMN1; SMN2KMT2AHSD17B10 | |
| SCHEMBL1093290 | 0.71 | APOBEC3G (0.52) | APOBEC3GALDH1A1SMN1; SMN2KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8907101-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-20130338111-A1 | Sulfonamide Derivatives | ICAGEN, INC. (US) | 2013-12-19 | — | — | US | disclosed |
| US-8541588-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2013-09-24 | — | — | US | disclosed |
| US-20120149679-A1 | Sulfonamide Derivatives | ICAGEN, INC. | 2012-06-14 | — | — | US | disclosed |
| US-8153814-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2012-04-10 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | SULT2A1, SULT1A1, TPST2 | APOBEC3G 4833/4885ALDH1A1 1369/4885SMN1; SMN2 86/4885 |
| US-20130338111-A1 | Sulfonamide Derivatives | SULT2A1, SULT1A1, TPST2 | APOBEC3G 4833/4885ALDH1A1 1369/4885SMN1; SMN2 86/4885 |
| US-20120149679-A1 | Sulfonamide Derivatives | SULT2A1, SULT1A1, TPST2 | APOBEC3G 4833/4885ALDH1A1 1369/4885SMN1; SMN2 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.